Changes in hormones during the intervention by study group
| Therapeutic CPAP (n=37) | CPAP withdrawal (n=33) | P value* | |||||
| Baseline | Follow-up | Delta follow-up minus baseline | Baseline | Follow-up | Delta follow-up minus baseline | ||
| Dihydroxyphenylglycol, ng/mL | 719.75±178.81 | 731.66±205 78 | +11.91±167.97 | 754.92±234.63 | 857.50±261.41 | +105.28±203.70 | 0.0087 |
| Epinephrine, ng/mL | 36.06±26.16 | 36.35±24.77 | +0.29±22.89 | 27.37±20.46 | 31.09±27.81 | 3.72±23.95 | 0.7026 |
| Norepinephrine, ng/mL | 294.11±113.74 | 299.92±106.54 | +5.81±104.83 | 337.32±154.59 | 374.80±132.52 | 37.48±150.03 | 0.0062 |
| Cortisol, pg/mL | 142.33±51.67 | 136.50±47.25 | −5.83±50.89 | 140.32±49.47 | 160.33±45.71 | 20.01±57.63 | 0.0289 |
| 18OH-Cortisol, pg/mL | 0.63±0.27 | 0.64±0.25 | +0.01±0.29 | 0.61±0.32 | 0.68±0.29 | 0.07±0.25 | 0.5069 |
| Cortisone, pg/mL | 19.63±4.25 | 20.16±3.79 | +0.53±5.07 | 19.29±5.13 | 21.35±3.67 | 2.06±5.47 | 0.2949 |
| 11-Deoxycortisol, pg/mL | 0.57±0.43 | 0.50±0.42 | −0.07±0.44 | 0.59±0.59 | 0.61±0.43 | +0.02±0.67 | 0.3514 |
| 21-Deoxycortisol, pg/mL | 0.08±0.13 | 0.06±0.11 | +0.02±0.09 | 0.05±0.06 | 0.07±0.10 | +0.02±0.10 | 0.1093 |
| 18-oxo-Cortisol, pg/mL | 0.02±0.01 | 0.02±0.01 | 0±0.01 | 0.02±0.01 | 0.02±0.01 | 0±0.01 | 0.6712 |
| Aldosterone, pg/mL | 0.08±0.05 | 0.08±0.05 | 0±0.04 | 0.07±0.05 | 0.09±0.05 | 0.02±0.04 | 0.2023 |
| Corticosterone, pg/mL | 4.13±4.06 | 3.51±4.33 | −0.62±3.42 | 4.51±3.94 | 5.39±3.89 | +0.88±4.44 | 0.8125 |
| 11-Deoxycorticosterone, pg/mL | 0.05±0.04 | 0.04±0.04 | −0.01±0.03 | 0.06±0.06 | 0.05±0.04 | −0.01±0.06 | 0.3514 |
| Renin, pg/mL | 32.66±60.63 | 41.32±73.76 | +8.66±97.31 | 49.20±96.09 | 50.75±94.53 | +1.55±113.36 | 0.9051 |
*Adjusted for sex, body mass index, age and presence of hypertension. Treatment effects are shown in figure 1.